For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Sedrakyan	Beyer	Blegen	Gutman	Howard	Massey	Nowak	Rizzo	Sanders	Sartor	Stecker	Wong	Marciniak	Conley	Rosenthal	Voting Member Average	Overall Average
1. How confident are you that existing evidence is sufficient to confirm the clinical validity (defined as how reliably test results is associated with the presence of the disease or target condition) of each of the following?																	
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence																	
a. DNA- or RNA-based testing to predict tissue of origin for CUP.	3	4	4	2	4	3	3	3	3	4	3	3	3	3	2	**3.25**	**3.13**
b. 'FISH' testing for cervical cancer/pre-cancer in patients with atypical squamous cells of unknown significance ('ASCUS') / low-grade intraepithelial squamous lesion ('LSIL').	1	2	2	2	2	2	2	1	1	2	2	1	2	1	1	**1.67**	**1.60**

For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Sedrakyan	Beyer	Blegen	Gutman	Howard	Massey	Nowak	Rizzo	Sanders	Sartor	Stecker	Wong	Marciniak	Conley	Rosenthal	Voting Member Average	Overall Average
2 How confident are you that there is sufficient evidence to determine whether genetic testing of tumor tissue *affects* health outcomes (including benefits and harms) for patients with cancer whose anticancer treatment strategy is guided by the results of each of the following?																	
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence																	
a. DNA- or RNA-based testing to predict tissue of origin for CUP.	2	3	1	2	2	2	2	3	2	3	1	2	2	2	2	**2.08**	**2.07**
b. FISH testing for cervical cancer/pre-cancer in patients with ASCUS/LSIL. **The mean vote was less than 2.5 so the panel members did not vote on question 1b.**																**#DIV/0!**	**#DIV/0!**

For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Sedrakyan	Beyer	Blegen	Gutman	Howard	Massey	Nowak	Rizzo	Sanders	Sartor	Stecker	Wong	Marciniak	Conley	Rosenthal	Voting Member Average	Overall Average
3 How confident are you that there is sufficient evidence to conclude that genetic testing of tumor tissue *improves* overall health outcomes (including benefits and harms) for patients with cancer whose anticancer treatment strategy is guided by the results of each of the following?																	
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence																	
a. DNA- or RNA-based testing to predict tissue of origin for CUP. **The mean vote was less than 2.5 so the panel members did not vote on question 2a.**																**#DIV/0!**	**#DIV/0!**
b. FISH testing for cervical cancer/pre-cancer in patients with ASCUS/LSIL. **The mean vote was less than 2.5 so the panel members did not vote on question 2b.**																**#DIV/0!**	**#DIV/0!**